Polly Baker1, Sarah Louise Davies2, Joanne Larkin3, Daniel Moult4, Sally Benton5, Andrew Roberts6, Timothy Harris7. 1. Department of Sports Medicine and Rehabilitation, Defence Medical Rehabilitation Centre, Headley Court, Surrey, UK. 2. Department of Sports Medicine, Rheumatology and Rehabilitation, Royal National Orthopaedic Hospital, London, Stanmore, UK. 3. Institute of Sports, Exercise and Health, University College London, London, UK. 4. Department of Anaesthesia and Intensive Care Medicine, Kings College London, London, UK. 5. Department Clinical Biochemistry, Royal London Hospital, Barts and the London NHS Trust, London, UK. 6. Department of Research, Defence Medical Rehabilitation Centre, Headley Court, Surrey, UK. 7. Department of Emergency Medicine and Research, Queen Marys University London, London, UK.
Abstract
INTRODUCTION: Many studies have demonstrated a rise in troponin and brain natriuretic peptide (BNP) levels following prolonged and/or strenuous exercise. Only one study looked at athletes who collapse and this showed no difference in cardiac biomarkers between those who collapsed and those who completed without requiring medical attention. We set out to describe and quantify the changes in troponin and BNP in three groups of non-elite runners at the 2009 London marathon: those with and without known structural heart disease (SHD) and those who collapsed on completion. METHODS: The first group (recruited group, RG) was recruited at the prerace exhibition. This group had two subsets, runners with SHD and without (non-SHD). A second group was recruited from those who collapsed (collapsed group, CG). Blood was taken for troponin I (TnI), troponin T (TnT), high sensitivity TnT (HSTnT) and BNP. RESULTS: Cardiac biomarker levels increased in all groups following the marathon. No statistically significant difference was seen between the SHD and non-SHD subgroups. When comparing the RG and CG the number and degree of rise was greater in those who collapsed. A trend for the degree of rise of HSTnT was demonstrated. DISCUSSION: We identified runners with troponin levels that, in other circumstances, would raise concern for myocardial necrosis. However absence of adverse clinical sequelae would suggest this rise is physiological. The cause and clinical significance of the increased HSTnT levels seen in those that collapsed is yet to be fully elucidated. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
INTRODUCTION: Many studies have demonstrated a rise in troponin and brain natriuretic peptide (BNP) levels following prolonged and/or strenuous exercise. Only one study looked at athletes who collapse and this showed no difference in cardiac biomarkers between those who collapsed and those who completed without requiring medical attention. We set out to describe and quantify the changes in troponin and BNP in three groups of non-elite runners at the 2009 London marathon: those with and without known structural heart disease (SHD) and those who collapsed on completion. METHODS: The first group (recruited group, RG) was recruited at the prerace exhibition. This group had two subsets, runners with SHD and without (non-SHD). A second group was recruited from those who collapsed (collapsed group, CG). Blood was taken for troponin I (TnI), troponin T (TnT), high sensitivity TnT (HSTnT) and BNP. RESULTS: Cardiac biomarker levels increased in all groups following the marathon. No statistically significant difference was seen between the SHD and non-SHD subgroups. When comparing the RG and CG the number and degree of rise was greater in those who collapsed. A trend for the degree of rise of HSTnT was demonstrated. DISCUSSION: We identified runners with troponin levels that, in other circumstances, would raise concern for myocardial necrosis. However absence of adverse clinical sequelae would suggest this rise is physiological. The cause and clinical significance of the increased HSTnT levels seen in those that collapsed is yet to be fully elucidated. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Renata J M Engler; Michael R Nelson; Limone C Collins; Christina Spooner; Brian A Hemann; Barnett T Gibbs; J Edwin Atwood; Robin S Howard; Audrey S Chang; Daniel L Cruser; Daniel G Gates; Marina N Vernalis; Marguerite S Lengkeek; Bruce M McClenathan; Allan S Jaffe; Leslie T Cooper; Steve Black; Christopher Carlson; Christopher Wilson; Robert L Davis Journal: PLoS One Date: 2015-03-20 Impact factor: 3.240
Authors: Eslam Samaha; Audrey Avila; Mohammad A Helwani; Arbi Ben Abdallah; Allan S Jaffe; Mitchell G Scott; Peter Nagele Journal: J Am Heart Assoc Date: 2019-03-19 Impact factor: 5.501
Authors: Caroline Le Goff; Magalie Viallon; Jean-François Kaux; Pierre Andonian; Kevin Moulin; Laurence Seidel; Guido Giardini; Laurent Gergelé; Pierre Croisille; Etienne Cavalier; Gregoire P Millet Journal: Front Cardiovasc Med Date: 2022-03-07